Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study
Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy‐based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study...
Saved in:
Published in | Hepatology communications Vol. 5; no. 6; pp. 938 - 946 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
01.06.2021
John Wiley and Sons Inc Wolters Kluwer Health/LWW |
Subjects | |
Online Access | Get full text |
ISSN | 2471-254X 2471-254X |
DOI | 10.1002/hep4.1689 |
Cover
Summary: | Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy‐based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive of histologic versus empiric clinical diagnosis of NAFLD in real‐world practice. Adults from TARGET‐NASH were included in this study. Descriptive statistics are provided for the cohort and compare the characteristics of histologic NAFLD versus patients with clinically diagnosed NAFLD, followed by logistic regression and machine‐learning models to describe predictors of liver biopsy. The records of 3,474 subjects were analyzed; median age was 59 years, 59% were female, 75% were White, and median body mass index was 32 kg/m2. Using histologic and/or clinical criteria, a diagnosis of nonalcoholic steatohepatitis was made in 37%, and cirrhosis in 33%. Comorbid conditions included cardiovascular disease (19%), mental health diagnoses (49%), and osteoarthritis (10%). Predictors of a biopsy diagnosis included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). ALT increased the odds of liver biopsy by 14% per 10‐point rise. Machine‐learning analyses showed non‐White patients with ALT <69 had only a 0.06 probability of undergoing liver biopsy. ALT was the dominant variable that determined liver biopsy. Conclusions: In this real‐world cohort of patients with NAFLD, two‐thirds of patients did not have a liver biopsy. These patients were more likely to be non‐White, older, with a normal ALT, showing potential gaps in or knowledge about this population.
The aim of this study was to determine patient factors predictive of histologic versus empiric clinical diagnosis of NAFLD in real world practice in adults enrolled in the TARGET‐NASH study. The records of 3,474 subjects were analyzed; median age was 59 years, 59% were female, 75% were white, and median BMI was 32 kg/m2. In this real‐world cohort of patients with NAFLD, two thirds of patients did not have a liver biopsy; these patients were more likely to be non‐white, older, with a normal ALT. |
---|---|
Bibliography: | Potential conflict of interest: Dr. Vos consults for Target Pharmasolutions, Eli Lilly, and Novo Nordisk. Dr. Neuschwander‐Tertri owns stock in HepGene. He received grants from Allergan, BMS, Cirius, Enanta, Genfit, Gilead, Intercept, Madrigal, and NGM. Dr. Barritt consults for Target RWE and Intercept Pharmaceuticals. Dr. Cusi advises and consults for Astra‐Zeneca, BMS, Coherus, Genentech, and Prosciento. He advises Inventiva. He consults for Allergan, Axcella, Boehringer Ingelheim, Deuterex, Eli Lilly, Fractyl, Genfit, Gilead, Janssen, Madrigal, Merck, Pfizer, Poxel, Sanofi‐Aventis, and Viscera Labs. He received grants from Cirius, Echosens, Inventiva, Novartis, Nordic, Novo Nordisk, and Zydus. Dr. Reddy advises and received grants from Gilead. He advises Mallinckrodt. He received grants from BMS, Merck, Intercept, Sequana, Exact Sciences, NASH‐Target, and HCC‐Target. He is on the DSMB for Novartis. Dr. Lok consults for and received grants from Target. She advises Novo Nordisk. She received grants from BMS. Dr. Loomba consults and received grants from AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, Galmed, Gilead, Intercept, Janssen, Madrigal, NGM Biopharmaceuticals, and Pfizer. He consults for Anaylam/Regeneron, Amgen, Arrowhead, CohBar, Glympse Bio, Inipharm, Ionis, Metacrine, Novartis, Novo Nordisk, Sagimet, 89 Bio, and Viking Therapeutics. He received grants from Allergan, Boheringer‐Ingelheim, Galectin, Genfit, Inventiva, Merck, and Siemens. He is the co‐founder of Liponexus. Dr. Mospan is employed by Target RWE. Dr. Trinh owns stock in, consults for, advises, is on the speakers’ bureau for, and received grants from Gilead. He received grants from Assembly. Dr. Sanyal consults and received grants from Conatus, Gilead, Echosens‐Sandhill, Malinckrodt, Salix, Novartis, Galectin, and Sequana. He consults and owns stock in GenFit, Hemoshear, Durect, and Indalo. He consults for Immuron, Intercept, Pfizer, Boehringer Ingelheim, Nimbus, Lilly, Merck, Novo Nordisk, Fractyl, Allergan, Chemomab, Affimmune, Teva, Ardelyx, Terns, ENYO, Birdrock, Albireo, Sanofi, Takeda, Janssen, Zydus, BASF, AMRA, Perspectum, Owl, Poxel, Servier, Second Genome, General Electric, and 89 Bio. He received grants from BMS. He received royalties from Elsevier and Uptodate. He owns stock in Exhalenz, Akarna and Tiziana. He is employed by Sanyal Bio. Clinical trial number: NCT02815891. Supported by Target RWE, sponsor of the TARGET‐NASH study. TARGET‐NASH is a collaboration among academic and community investigators and the pharmaceutical industry. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2471-254X 2471-254X |
DOI: | 10.1002/hep4.1689 |